Interventions for female pattern hair loss Edited (no change to conclusions), comment added to review

Abstract

Abstract
Background

Female pattern hair loss (FPHL), or androgenic alopecia, is the most common type of hair loss affecting women. It is characterised by progressive shortening of the duration of the growth phase of the hair with successive hair cycles, and progressive follicular miniaturisation with conversion of terminal to vellus hair follicles (terminal hairs are thicker and longer, while vellus hairs are soft, fine, and short). The frontal hair line may or may not be preserved. Hair loss can have a serious psychological impact on women.

Objectives

To determine the efficacy and safety of the available options for the treatment of female pattern hair loss in women.

Search methods

We updated our searches of the following databases to July 2015: the Cochrane Skin Group Specialised Register, CENTRAL in the Cochrane Library (2015, Issue 6), MEDLINE (from 1946), EMBASE (from 1974), PsycINFO (from 1872), AMED (from 1985), LILACS (from 1982), PubMed (from 1947), and Web of Science (from 1945). We also searched five trial registries and checked the reference lists of included and excluded studies.

Selection criteria

We included randomised controlled trials that assessed the efficacy of interventions for FPHL in women.

Data collection and analysis

Two review authors independently assessed trial quality, extracted data and carried out analyses.

Main results

We included 47 trials, with 5290 participants, of which 25 trials were new to this update. Only five trials were at 'low risk of bias', 26 were at 'unclear risk', and 16 were at 'high risk of bias'.

The included trials evaluated a wide range of interventions, and 17 studies evaluated minoxidil. Pooled data from six studies indicated that a greater proportion of participants (157/593) treated with minoxidil (2% and one study with 1%) reported a moderate to marked increase in their hair regrowth when compared with placebo (77/555) (risk ratio (RR) = 1.93, 95% confidence interval (CI) 1.51 to 2.47; moderate quality evidence). These results were confirmed by the investigator‐rated assessments in seven studies with 1181 participants (RR 2.35, 95% CI 1.68 to 3.28; moderate quality evidence). Only one study reported on quality of life (QoL) (260 participants), albeit inadequately (low quality evidence). There was an important increase of 13.18 in total hair count per cm² in the minoxidil group compared to the placebo group (95% CI 10.92 to 15.44; low quality evidence) in eight studies (1242 participants). There were 40/407 adverse events in the twice daily minoxidil 2% group versus 28/320 in the placebo group (RR 1.24, 95% CI 0.82 to 1.87; low quality evidence). There was also no statistically significant difference in adverse events between any of the individual concentrations against placebo.

Four studies (1006 participants) evaluated minoxidil 2% versus 5%. In one study, 25/57 participants in the minoxidil 2% group experienced moderate to greatly increased hair regrowth versus 22/56 in the 5% group (RR 1.12, 95% CI 0.72 to 1.73). In another study, 209 participants experienced no difference based on a visual analogue scale (P = 0.062; low quality evidence). The assessments of the investigators based on three studies (586 participants) were in agreement with these findings (moderate quality evidence). One study assessed QoL (209 participants) and reported limited data (low quality evidence). Four trials (1006 participants) did not show a difference in number of adverse events between the two concentrations (RR 1.02, 95% CI 0.91 to 1.20; low quality evidence). Both concentrations did not show a difference in increase in total hair count at end of study in three trials with 631 participants (mean difference (MD) −2.12, 95% CI −5.47 to 1.23; low quality evidence).

Three studies investigated finasteride 1 mg compared to placebo. In the finasteride group 30/67 participants experienced improvement compared to 33/70 in the placebo group (RR 0.95, 95% CI 0.66 to 1.37; low quality evidence). This was consistent with the investigators' assessments (RR 0.77, 95% CI 0.31 to 1.90; low quality evidence). QoL was not assessed. Only one study addressed adverse events (137 participants) (RR 1.03, 95% CI 0.45 to 2.34; low quality evidence). In two studies (219 participants) there was no clinically meaningful difference in change of hair count, whilst one study (12 participants) favoured finasteride (low quality evidence).

Two studies (141 participants) evaluated low‐level laser comb therapy compared to a sham device. According to the participants, the low‐level laser comb was not more effective than the sham device (RR 1.54, 95% CI 0.96 to 2.49; and RR 1.18, 95% CI 0.74 to 1.89; moderate quality evidence). However, there was a difference in favour of low‐level laser comb for change from baseline in hair count (MD 17.40, 95% CI 9.74 to 25.06; and MD 17.60, 95% CI 11.97 to 23.23; low quality evidence). These studies did not assess QoL and did not report adverse events per treatment arm and only in a generic way (low quality evidence). Low‐level laser therapy against sham comparisons in two separate studies also showed an increase in total hair count but with limited further data.

Single studies addressed the other comparisons and provided limited evidence of either the efficacy or safety of these interventions, or were unlikely to be examined in future trials.

Authors' conclusions

Although there was a predominance of included studies at unclear to high risk of bias, there was evidence to support the efficacy and safety of topical minoxidil in the treatment of FPHL (mainly moderate to low quality evidence). Furthermore, there was no difference in effect between the minoxidil 2% and 5% with the quality of evidence rated moderate to low for most outcomes. Finasteride was no more effective than placebo (low quality evidence). There were inconsistent results in the studies that evaluated laser devices (moderate to low quality evidence), but there was an improvement in total hair count measured from baseline.

Further randomised controlled trials of other widely‐used treatments, such as spironolactone, finasteride (different dosages), dutasteride, cyproterone acetate, and laser‐based therapy are needed.

Author(s)

Esther J van Zuuren, Zbys Fedorowicz, Jan Schoones

Abstract

Plain language summary

 Treatments for female pattern hair loss 

 Review question 

Which treatments are effective and safe for female pattern hair loss (FPHL)?

 Background 

The most common type of hair loss in women is FPHL, also known as androgenic alopecia. Unlike men, women do not go bald, but have hair thinning predominantly over the top and front of the head. It can occur at any time, from puberty until later in life. However, it occurs more frequently in postmenopausal women.

The diagnosis is supported by careful history taking (including family history). Other causes should be considered; therefore, a clinical examination and laboratory tests may be necessary. FPHL can have a significant impact on self‐consciousness, and the damage to a woman's self‐confidence can affect her quality of life (QoL), leading to feelings of unattractiveness, shame, discomfort, emotional stress, and low self‐esteem.

 Study characteristics 

We examined the available evidence up to 7 July 2015. Forty‐seven studies, which included 5290 women, met the inclusion criteria of this Cochrane review. The mean age of participants in the studies varied from 27 to 57 years. We assessed over half of the included studies as at unclear risk of bias, 16 as high risk, and only five studies as low risk of bias. Funding was provided in 26 of the 47 studies, mainly by pharmaceutical companies.

 Key results 

This Cochrane review found that minoxidil is more effective than placebo. In six studies, the proportion of women that experienced at least moderate hair regrowth was twice as high in the minoxidil group compared to the placebo group. This was confirmed by the investigators assessments in seven studies. In eight studies, there was an important increase in total hair count per cm² in the minoxidil group compared to the placebo group. QoL was only assessed in one study and it was unclear from the data if there was an important improvement. The number of adverse events was similar for both groups. These were mostly mild, consisting of itch, skin irritation, dermatitis, and additional hair growth on areas other than the scalp.

Four studies compared minoxidil (2%) to minoxidil (5%), but none of the studies indicated any benefit of the higher concentration over the lower concentration. The number of adverse events did not differ between the two groups. Minoxidil should not be used in pregnant or lactating women.

Three studies compared finasteride to placebo. Finasteride is only approved in men for treatment of hair loss as well as for enlarged prostate. In one of the three studies the opinion of both the participants and investigators were evaluated but finasteride was shown to be no more effective than placebo. Hair count improved only in the finasteride group in a small study with 12 participants, but not in the other two studies (219 participants). Adverse events were only addressed in one study and these were similar in both groups. The investigators of these studies did not assess QoL.

Laser comb therapy did not appear to be more effective than sham therapy according to the participants in two studies with 141 participants. Nonetheless an important increase in hair growth was reported in both these studies. QoL was not addressed, and adverse events were not reported per intervention group, making these data less usable.

Individual studies investigated most of the other interventions and comparisons, and we could not make any firm conclusions about the efficacy or safety of these other interventions.

Although it is generally acknowledged that renewed hair shedding occurs relatively soon after discontinuation of treatment, none of the included studies reported data on the sustainability of the treatment effect, nor on the possible impact of hair regrowth, reflected by a decrease in time spent by women on hair styling or the use of wigs.

 Quality of the evidence 

We rated the quality of evidence for most outcomes as moderate or low. The lower quality of evidence was mainly caused by risk of bias in studies (e.g. no blinding) or a small sample size making the results less precise.

Author(s)

Esther J van Zuuren, Zbys Fedorowicz, Jan Schoones

Reviewer's Conclusions

Authors' conclusions

Implications for practice

Based on only those studies that are most likely to have provided reliable results (i.e. reproducible, repeatable, and therefore valid), and selecting the most rigorously described and conducted studies, we conclude that there is mainly moderate to low quality evidence to support the efficacy of only one of the interventions for female pattern hair loss (FPHL), notably minoxidil.

Minoxidil (2%) topical solution twice daily appears to be effective and safe, and minoxidil (5%) used once daily may be as effective as minoxidil (2%) used twice daily, which is likely to result in improved adherence. However, the higher concentration of minoxidil (5%) is only registered for therapeutic management of FPHL in a small number of countries worldwide.

Although finasteride continues to be prescribed for treatment of women with FPHL, this therapeutic option does not appear to be supported by current research based on randomised controlled trials. Low‐level laser therapy options are attracting interest but the results so far have been inconsistent.

Clinical decision‐making on the choice of intervention for FPHL should be based on high‐level evidence if it is available, but in the absence of such evidence for any other specific intervention, these decisions should continue to be guided by clinical experience and peoples' individual characteristics and preferences until further evidence for these other interventions becomes available.

In view of the fact that there may be a delay before any treatment effect can be noticed, and as most of the available treatments fail to achieve the desired end result, cosmetic aids and hair transplant surgery need to be included in the decision‐making process. Furthermore, physicians should also try to address the psychosocial impact, coping mechanisms, and QoL issues when treating women with FPHL.

Implications for research

It is widely perceived that 2% minoxidil is more effective than the 1% concentration, and this is reflected in the fact that the 2% concentration is most frequently registered worldwide for FPHL. However, the results from one study included in this review indicate that 1% minoxidil does not appear any less effective than 2% minoxidil and is also associated with a potentially lower number of adverse events. There was also evidence (mainly moderate to low quality) that 5% minoxidil once daily was as effective as 2% minoxidil twice daily; a factor which may be important in improving adherence in future clinical trials.

There is also an urgent need for high‐quality, well‐designed, and rigorously‐reported studies of other widely‐used treatments, such as spironolactone, finasteride (at different dosages), dutasteride, cyproterone acetate, and laser‐based therapy. Conceivably, some studies listed in the 'Characteristics of ongoing studies' section of this review will be able to provide answers to these remaining questions in the future.

There was wide variability in the conduct and the quality of reporting of many trials. A major area for improvement would be in the standardisation of outcome reporting in any future research. The use of proprietary severity scales and non‐standardised scales significantly hampered our ability to combine study results for a meta‐analysis. Outcomes collected in future trials should be primarily based on a standardised scale of the participant's assessment of the treatment efficacy, and they should also have a greater emphasis on changes in QoL as a result of the interventions. Standardised and uniform scales should be developed and used for physicians' assessments, and these should reliably reflect the proportion of participants with investigator‐rated clinically significant hair regrowth and mean change in total hair count from baseline to the end of the study. Follow‐up studies addressing the sustainability of hair regrowth after discontinuation of treatment should be taken into account as they constitute an important outcome for participants. Another important patient‐reported outcome should be the impact of the hair regrowth reflected by a decrease in the time spent by women on hair styling, including the use of wigs.

Future randomised controlled trials must be well‐designed, well‐conducted, and adequately delivered, with subsequent reporting, including high‐quality descriptions of all aspects of methodology. Rigorous reporting needs to conform to the Consolidated Standards of Reporting Trials (CONSORT) statement, and this will enable appraisal and interpretation of results, and accurate judgements to be made about the risk of bias and the overall quality of the evidence. Although it is uncertain whether reported quality mirrors actual study conduct, it is noteworthy that studies with unclear methodology have been shown to produce biased estimates of treatment effects (Schulz 1995). Adherence to guidelines, such as the CONSORT statement, would help ensure complete reporting.

For further research recommendations based on the EPICOT (evidence, population, intervention, comparison, outcomes, and time) format (Brown 2006), see .

Get full text at The Cochrane Library

Interventions for female pattern hair loss Edited (no change to conclusions), comment added to review is a sample topic from the Cochrane Abstracts.

To view other topics, please or .

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. .